AVITA Medical (RCEL) CFO adds 2,000 shares in open-market buy
AVITA Medical (RCEL) CFO David D. O'Toole purchased 2,000 shares of common stock in an open-market transaction at $4.26 per share, totaling $8,520. Following this acquisition, O'Toole directly holds 145,927 shares, which include unvested restricted stock units. This insider buy signals confidence in the company, with the transaction detailed in a Form 4 SEC filing dated May 20, 2026.
AVITA Medical (RCEL) CFO adds 2,000 shares in open-market purchase
AVITA Medical, Inc.'s CFO, David D. O'Toole, purchased 2,000 shares of common stock at $4.24 per share through an open-market transaction. This purchase increases his direct holdings to 143,927 shares, which includes unvested restricted stock units. The transaction was filed on Form 4 and indicates a net buy of 2,000 shares valued at $8,480.
Two AVITA Medical investor Q&As with CEO Cary Vance on May 20–21
AVITA Medical (NASDAQ: RCEL) will host two investor Q&A events featuring CEO Cary Vance in May 2026. The first is a webinar on May 20, 2026, at 4:00 p.m. PT (May 21, 2026, at 9:00 a.m. AEST), reviewing Q1 2026 earnings. The second is an in-person armchair discussion in Melbourne on May 21, 2026, at 4:00 p.m. AEST, focusing on the company's acute wound care platform, commercial progress, and 2026 priorities.
AVITA Medical, Inc. (NASDAQ:RCEL) Q1 2026 Earnings Call Transcript
AVITA Medical, Inc. reported its Q1 2026 earnings, with revenues of approximately $19.3 million, up 4% year-over-year and 10% sequentially, meeting EPS expectations of $-0.35. The company leadership emphasized stabilization and improved operational efficiency, driven by normalization of RECELL reimbursement and early traction for Cohealyx. AVITA Medical reaffirmed its full-year 2026 net revenue guidance of $80 million to $85 million, expecting continued sequential growth.
AVITA Medical Q1 2026 earnings preview
This article provides an earnings preview for AVITA Medical's Q1 2026 results. As the content is empty, no specific details regarding financial expectations or previous performance can be included in this summary.
Avita Medical Raised to Buy From Hold by Lake Street
Lake Street has upgraded Avita Medical's rating from Hold to Buy. This change in rating indicates a more positive outlook from the analyst firm regarding the company's stock.
Avita Medical, Inc. Stock 12‑Month Price Target Raised to $6.99, Implies 60% Upside
Avita Medical, Inc.'s average 12-month price target has been increased to $6.99 by analysts, up from $6.67, with forecasts ranging from $4.24 to $10.84 per share. This updated target suggests a potential upside of approximately 60% based on the May 14 closing price. The consensus rating for RCEL remains "Buy" among the 8 covering analysts.
Avita Medical Q1 Earnings Call Highlights
Avita Medical reported strong Q1 2026 revenue growth of approximately $19.3 million, a 4% increase year-over-year, and reaffirmed its full-year revenue guidance of $80 million to $85 million. The company highlighted normalizing reimbursement conditions for its RECELL product, early but encouraging adoption of Cohealyx, and a significant decrease in operating expenses. Management also noted improved cash position and increased confidence in future growth as demand patterns become more consistent.
Avita Medical Posts Narrower Q1 Loss, Higher Revenue; Reaffirms Full-Year 2026 Outlook
Avita Medical reported a narrower loss and increased revenue for its first quarter, while reaffirming its full-year 2026 financial outlook. These results indicate positive momentum for the company as it progresses through the fiscal year.
Avita Medical stock (US0301011039): Q1 2026 results and revenue details
Avita Medical reported its Q1 2026 financial results on May 14, 2026, providing key insights into its revenue trends and demand for wound care products. The company's business model is centered on therapeutic acute wound care, with products aimed at hospitals and clinical settings in the U.S., Japan, Europe, Australia, and the U.K. Investors are keenly watching these reports for signs of product adoption, commercial reimbursement, and operational leverage, as well as the impact of its Nasdaq and ASX listings.
AVITA Medical Reports First Quarter 2026 Financial Results
AVITA Medical reported strong Q1 2026 financial results, with total revenue up 4% year-over-year to $19.3 million, driven by contributions from Cohealyx and improved RECELL utilization. The company also announced the appointment of Cary Vance as President and CEO, a gross profit margin of 81.7%, and a significant decrease in operating expenses. AVITA Medical reaffirmed its full-year 2026 revenue guidance of $80 to $85 million.
AVITA Medical (RCEL) Q1 2026 revenue rises 4% as losses narrow and 2026 outlook held
AVITA Medical reported a 4% year-over-year revenue increase to $19.3 million in Q1 2026, with net losses narrowing to $10.6 million from $13.9 million in the prior year. The company reaffirmed its full-year 2026 revenue guidance of $80 million to $85 million, citing improved RECELL utilization and contributions from Cohealyx. Operating expenses decreased by 11% due to cost optimization efforts, although cash use was higher in Q1 but is expected to significantly decrease in Q2.
Burn treatment firm AVITA wins 10-year BARDA deal worth up to $25.5M
AVITA Medical (NASDAQ: RCEL) announced its Q1 2026 financial results, reporting revenue of $19.3 million, a 4% year-over-year increase, and reaffirming its full-year 2026 revenue guidance of $80-$85 million. The company also disclosed a 10-year BARDA agreement worth up to $25.5 million for U.S. burn preparedness and positive interim data from its Cohealyx I study. Additionally, AVITA Medical announced leadership changes with Cary Vance appointed as CEO and Jan Stern Reed as Board Chair.
AVITA Medical Inc expected to post a loss of 28 cents a share - Earnings Preview
AVITA Medical Inc (RCEL) is projected to report a loss of 28 cents per share in its upcoming earnings. This forecast is a key piece of information for investors and is provided by Refinitiv. The article acts as an earnings preview for the company.
Avita Medical stock (US0301011039): Shares surged 7.75% in July 2025
Avita Medical stock (RCEL) saw significant volatility, with a 7.75% surge on July 23, 2025, reaching $6.26, driven by a pivot bottom buy signal. The company, which specializes in regenerative tissue technology with its lead product ReCell, later experienced a 21% drop due to legal scrutiny. The article highlights Avita Medical's core business, revenue drivers, and competitive position in the advanced wound care market, emphasizing its relevance to US investors in regenerative medicine.
Avita Medical Inc. (NASDAQ:RCEL) Given Consensus Rating of "Hold" by Brokerages
Avita Medical Inc. (NASDAQ:RCEL) has received a consensus "Hold" rating from six brokerages, with an average 12-month price target of $6.63. Recent analyst actions have been mixed, including price target adjustments and varied ratings from "outperform" to "strong sell." Institutional investors hold 27.66% of the company's shares.
AVITA Medical (CHIA:AVH) - Stock Analysis
AVITA Medical (CHIA:AVH) is analyzed as 52.2% undervalued, with earnings forecast to grow 57.24% annually. The company operates in acute wound care, with recent developments including the appointment of a new CEO, TGA certification for RECELL GO in Australia and New Zealand, and positive interim results from its Cohealyx-I study accelerating skin grafting. Financial risks include negative shareholder equity and past dilution, but the company is expected to become profitable by 2024 according to analyst forecasts.
AVITA Medical (Nasdaq:RCEL) - Stock Analysis
This Simply Wall St analysis provides an overview of AVITA Medical (RCEL), highlighting its valuation, future growth prospects, past performance, financial health, and recent news. The company is noted to be trading below its estimated fair value with strong earnings growth forecasts, despite identified risks such as negative shareholder equity and a volatile share price. Recent announcements include the appointment of a new CEO, TGA certification for RECELL GO in Australia and New Zealand, and positive interim results from the Cohealyx-I study.
Avita Medical (RCEL) Expected to Announce Earnings on Thursday
Avita Medical (NASDAQ:RCEL) is expected to announce its Q1 2026 earnings after market close on Thursday, May 14th. Analysts forecast earnings of ($0.35) per share and revenue of $18.2960 million. The company's stock shows a current market capitalization of $136.05 million, and analysts hold a consensus "Hold" rating with an average price target of $6.63.
Cary Vance becomes AVITA Medical (NASDAQ: RCEL) CEO as Board elevates Jan Stern Reed to Chair
AVITA Medical (NASDAQ: RCEL) has appointed Cary Vance as its permanent President and Chief Executive Officer, effective April 30, 2026, after he served as Interim CEO since October 2025. Concurrently, Jan Stern Reed has been named Chair of the Board. Vance's compensation package includes a base salary of $702,000, an 80% annual bonus target, and significant equity awards, formalizing the company's leadership structure.
AVITA Medical Names Cary Vance as Chief Executive Officer
AVITA Medical has appointed Cary Vance as its President and Chief Executive Officer, effective immediately, following his successful interim tenure since October 2025. Concurrently, Jan Stern Reed has been elected as the new Chair of the Avita Medical Board. The Board expressed confidence in Vance's leadership, operational discipline, and deep industry experience to guide the company into a period of growth and continued success in acute wound care.
AVITA Medical appoints Cary Vance as permanent CEO
AVITA Medical has officially appointed Cary Vance as its permanent Chief Executive Officer. Vance had previously served as interim CEO for the company. This appointment signifies a stabilization in leadership for the medical device firm.
AVITA Medical names Cary Vance as permanent CEO By Investing.com
AVITA Medical, Inc. has officially appointed Cary Vance as its permanent President and Chief Executive Officer, effective immediately. Vance had been serving as Interim CEO since October 2025 and also held the Chairman position since 2025. The medical device company, valued at $131 million, specializes in acute wound care products and recently secured a 10-year, $25.5 million agreement with BARDA for burn mass casualty preparedness.
After 6 months as interim CEO, Cary Vance gets AVITA's top job
AVITA Medical has appointed Cary Vance as its permanent President and Chief Executive Officer, effective April 30, 2026, after he served as Interim CEO since October 2025. Jan Stern Reed has also been named Chair of the Board. The Board praised Vance for stabilizing the business, sharpening strategic focus, and rebuilding confidence during his interim tenure, with leadership now focused on scaling clinical adoption of AVITA’s acute wound care platform.
AVITA Medical Announces TGA Certification in Australia and Medsafe WAND Listing in New Zealand for RECELL GO
AVITA Medical has received TGA certification in Australia and Medsafe WAND listing in New Zealand for RECELL GO, its next-generation system for preparing RECELL Spray-On Skin. This regulatory clearance enables commercialization in both markets for treating burn and acute wounds, with an expected launch in the coming weeks by exclusive distribution partner Revolution Surgical. RECELL GO automates and standardizes the preparation process, improving efficiency and optimizing cell yield to expand access to this technology.
AVITA Medical gains regulatory clearance for RECELL GO in Australia
AVITA Medical has received regulatory clearance for its RECELL GO system in Australia and New Zealand, an automated device for preparing Spray-On Skin for burn and trauma wounds. The company's stock has seen volatility but analysts are revising earnings estimates upward, and the system is expected to be commercially launched in the coming weeks. This expansion builds on previous approvals in the US, Europe, UK, and Japan, aiming to improve access to the RECELL technology in the region.
Burn care tool cleared for sale in Australia and New Zealand
AVITA Medical announced that its RECELL GO system has received TGA certification in Australia and Medsafe WAND listing in New Zealand, allowing for its commercialization in both markets for burn and acute wound treatment. This next-generation system automates and standardizes the preparation of RECELL Spray-On Skin, reducing manual steps and clinical burden. Revolution Surgical, AVITA Medical's exclusive distributor, plans to launch the product in these markets within weeks.
AVITA Medical to Announce First Quarter 2026 Financial Results
AVITA Medical (NASDAQ: RCEL, ASX: AVH) will announce its first-quarter 2026 financial results after market close on Thursday, May 14, 2026. The company will host a conference call and webcast on the same day at 1:30 p.m. Pacific Time to discuss the results and business highlights. Details for webcast registration and the earnings call are provided for interested participants.
AVITA Medical to Announce First Quarter 2026 Financial Results
AVITA Medical, a therapeutic acute wound care company, announced it will report its first-quarter 2026 financial results after the U.S. financial markets close on Thursday, May 14, 2026. The company will host a conference call and webcast on the same day to discuss the results and recent business highlights. Details for webcast registration and conference call participation were provided for interested parties.
AVITA Medical schedules May 14 earnings release, 1:30 p.m. call
AVITA Medical (NASDAQ: RCEL) announced it will report its first quarter 2026 financial results after the U.S. market close on Thursday, May 14, 2026. The company will host a conference call and webcast at 1:30 p.m. PT (May 15, 2026, 6:30 a.m. AEST) to discuss the results and business highlights, with a replay available on their investor relations website. This announcement follows a period of significant company news, including a BARDA agreement and positive clinical trial data, and investors will be looking at revenue trends, execution updates, and guidance during the call.
AVITA Medical appoints Cary Vance as interim CEO
AVITA Medical has appointed Cary Vance as its interim CEO. This leadership change indicates a temporary strategic move for the company.
AVITA Medical appoints Cary Vance as interim CEO
AVITA Medical has appointed Cary Vance as its interim CEO. This transition comes as the medical company seeks new leadership. Further details about the change were not immediately available.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical Inc. - RCEL
Pomerantz LLP is investigating potential securities fraud claims against AVITA Medical Inc. (NASDAQ: RCEL) following a significant drop in its stock price. The investigation concerns the company's disclosure of a six-month backlog in unpaid provider claims for its ReCell product, attributing the issue to problems with Medicare & Medicaid Services contractors. This backlog allegedly impacted first-half demand and caused a 21% stock price fall on August 8, 2025.
Avita Medical Inc. (NASDAQ:RCEL) Receives Consensus Rating of "Hold" from Analysts
Six analysts have issued a consensus "Hold" rating for Avita Medical Inc. (NASDAQ:RCEL), with an average 12-month price target of $6.625. The company's stock opened at $5.16, with institutional investors holding approximately 27.66% of shares. Recent analyst reports vary, with some initiating or reaffirming "Buy" or "Outperform" ratings and others maintaining "Hold" or "Sell," contributing to the overall "Hold" consensus.
The pioneer behind spray-on skin wins burn care’s top honor
Professor Fiona Wood, founder of AVITA Medical (NASDAQ: RCEL), has been honored with the American Burn Association Lifetime Achievement Award for her pioneering development of spray-on skin technology (RECEEL) and over 30 years of leadership in burn care. The award recognizes her global contributions to clinical practice and research, which laid the foundation for modern wound healing approaches. Despite the prestigious recognition, RCEL's stock price declined by 7.86% on the day this news was published, likely influenced by broader market factors or profit-taking rather than the positive reputational event itself.
AVITA Medical Founder Fiona Wood Honored with Lifetime Achievement Award by American Burn Association
Professor Fiona Wood, founder of AVITA Medical, has received the Lifetime Achievement Award from the American Burn Association (ABA) for her pioneering contributions to burn care, including the development of RECELL Spray-On Skin. This recognition highlights her over three decades of work in transforming burn treatment and improving patient outcomes. The ABA's highest honor acknowledges her enduring legacy in research, education, and clinical practice, which continues to influence modern burn care globally.
AVITA Medical data shows faster wound healing results
AVITA Medical (ASX:AVH) has released interim data from its Cohealyx-I study, showing significantly faster wound bed preparation for full-thickness wounds. The study indicates a mean time to skin grafting of 13.6 days, a substantial improvement over the 33.2-day benchmark. These results suggest that Cohealyx could become a new standard of care in trauma.
AVITA Medical Announces Positive Interim Results from Cohealyx Study Demonstrating Accelerated Time to Skin Grafting
AVITA Medical announced positive interim results from its Cohealyx-I study, showing a significant reduction in the mean time to skin grafting for patients with full-thickness wounds. The study demonstrated a mean time of 13.6 days to grafting, compared to a 33.2-day benchmark, with high investigator satisfaction. These results highlight Cohealyx's potential to improve wound bed preparation, accelerate patient recovery, and drive broader adoption in clinical practice.
AVITA Medical Announces Positive Interim Results from Cohealyx® Study Demonstrating Accelerated Time to Skin Grafting
AVITA Medical has announced positive interim results from its Cohealyx-I study, demonstrating a significant reduction in the mean time to skin grafting for patients with full-thickness wounds. The study showed a reduction to 13.6 days compared to a 33.2-day real-world benchmark, representing a nearly 20-day improvement. These results highlight Cohealyx's potential to accelerate wound healing and improve patient outcomes, with high investigator satisfaction among both new and experienced users.
Skin grafts in 11 days: AVITA posts interim Cohealyx wound data
AVITA Medical (NASDAQ: RCEL) announced positive interim results from its Cohealyx-I study, demonstrating a significant reduction in the mean time to skin grafting to 13.6 days, compared to a 33.2-day benchmark. The 40-patient interim analysis showed a median time of 11 days, with 72% grafted within 14 days and 90% investigator satisfaction. The full dataset is anticipated in 2026, and the company plans to host a Key Opinion Leader webinar to discuss these findings.
AVITA Medical Announces Positive Interim Results from Cohealyx® Study
AVITA Medical announced positive interim results from its Cohealyx-I study, showing a significant reduction in the mean time to skin grafting for patients with full-thickness wounds. The collagen-based dermal matrix reduced grafting time by nearly 20 days compared to a benchmark, supporting earlier grafting and improved patient outcomes. The data highlights Cohealyx's potential as a differentiated solution for acute wound care, with high investigator satisfaction.
AVITA Medical, Inc. Investigated by the Portnoy Law Firm
The Portnoy Law Firm has launched an investigation into potential securities fraud concerning AVITA Medical, Inc. (NASDAQ: RCEL) after its stock plummeted following the release of Q2 2025 financial results. The decline was attributed to a six-month backlog in unpaid provider claims for AVITA's Recell product, caused by the Centers for Medicare & Medicaid Services failing to timely adjudicate claims, leading to reduced product utilization. Investors are encouraged to contact the law firm for a case evaluation regarding their losses.
[EFFECT] AVITA Medical, Inc. SEC Filing
This article reports on an SEC filing (Form EFFECT) by AVITA Medical, Inc. (AVHHL) indicating the effectiveness of a shelf registration statement (S-3) on April 9, 2026, at 4:30 P.M. The filing impact and sentiment are noted as "Neutral." The article also provides AVHHL's stock data and lists recent SEC filings.
AVITA Medical Secures 10-Year BARDA Agreement Worth Up to $25.5M to Bolster U.S. Burn Emergency Preparedness
AVITA Medical has signed a 10-year agreement with BARDA, valued at up to $25.5 million, to enhance U.S. burn emergency preparedness. This agreement ensures rapid nationwide access to AVITA's RECELL® product for mass casualty incidents, with AVITA maintaining inventory and providing logistics. The partnership builds on a decade-long collaboration, committing AVITA to support national readiness and public health.
AVITA Medical Secures 10-Year BARDA Agreement Worth Up to $25.5M to Bolster U.S. Burn Emergency Preparedness
AVITA Medical has signed a 10-year agreement with BARDA, valued at up to $25.5 million, to enhance U.S. preparedness for burn mass casualty incidents. This agreement ensures rapid access to AVITA's RECELL ® product, with BARDA having the option to procure up to 3,000 units over the contract term. This partnership extends a decade-long collaboration to advance burn care innovation and bolster public health readiness.
AVITA Medical secures $25.5M BARDA burn preparedness contract By Investing.com
AVITA Medical has signed a 10-year contract with BARDA worth up to $25.5 million to enhance national preparedness for mass casualty burn incidents. This agreement grants BARDA access to 3,000 units of AVITA's RECELL burn treatment product for immediate deployment and offers options for further procurement. The deal includes annual access-maintenance fees and readiness support, with AVITA Medical also providing logistics and quality assurance.
AVITA Medical Secures 10-Year BARDA Agreement Worth Up to $25.5M to Bolster U.S. Burn Emergency Preparedness
AVITA Medical has signed a 10-year agreement with BARDA, valued at up to $25.5 million, to enhance the U.S.'s preparedness for burn mass casualty incidents. Under this agreement, AVITA Medical will maintain an inventory of its RECELL products for immediate deployment and provide readiness support, ensuring rapid access to critical burn care during emergencies. This partnership expands on a decade-long collaboration focused on advancing burn care innovation and public health readiness.
AVITA Medical Secures 10-Year BARDA Agreement Worth Up to $25.5M to Bolster U.S. Burn Emergency Preparedness
AVITA Medical has signed a 10-year agreement with BARDA, valued at up to $25.5 million, to enhance U.S. preparedness for burn mass casualty incidents. The agreement ensures rapid nationwide access to AVITA Medical's RECELL product, which uses a patient's own skin to optimize wound healing. This partnership strengthens the nation's ability to respond to large-scale burn emergencies by maintaining an inventory for immediate deployment and providing logistical support.
AVITA wins U.S. burn response deal covering 3,000 emergency units
AVITA Medical has secured a 10-year agreement with BARDA under Project BioShield, valued at up to $25.5 million, to enhance the U.S.'s burn mass casualty preparedness. This contract provides BARDA access to 3,000 RECELL units for rapid deployment, along with options for additional procurement and readiness support. While $3.97 million is guaranteed revenue over the decade through access-maintenance and readiness fees, the remaining value is contingent on BARDA exercising its procurement options.
AVITA Medical Showcases Acute Burn and Wound Care Portfolio at ABA 2026, Featuring New Cohealyx Data
AVITA Medical is presenting new clinical data on its Cohealyx product at the 2026 American Burn Association (ABA) Annual Meeting, alongside showcasing real-world experience with RECELL and PermeaDerm. The company aims to highlight a comprehensive approach to wound management that improves patient outcomes, reduces hospital stays, and optimizes resource utilization. New data on Cohealyx will include an interim analysis from an ongoing multi-center study, evaluating time to skin grafting.
